Healthcare entity
They are better corroborated than the beat average, carrying 18.5 original sources each against 3.6 for the same window. Coverage clusters in regulation, which accounts for 3 of those 4, with the remainder spread across 1 other category. Of the tracked stories, 1 of 4 also mention #WeCount report, the most common co-covered peer.
Last mentioned: Mar 20, 2026
Entity pulse
Coverage balance Balanced directional read. Positive and negative coverage are within 0 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
They are better corroborated than the beat average, carrying 18.5 original sources each against 3.6 for the same window. Coverage clusters in regulation, which accounts for 3 of those 4, with the remainder spread across 1 other category. Of the tracked stories, 1 of 4 also mention #WeCount report, the most common co-covered peer. Across a 113-day span, the pace is roughly 0.2 stories per week. The 6.3 average consequence score is above the beat benchmark of 6.1 in the same window. We currently track 4 Healthcare stories that mention Food and Drug Administration (FDA), published between March 8, 2026 and June 28, 2026.
Computed from the 4 stories linked to this entity, with beat comparisons drawn from all 498 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Food and Drug Administration (FDA). Shared-story counts are live from our verified record — not editorial picks.
Industry Consensus
Scientific American and other major outlets report a definitive decline in global animal experiment volumes.
Major CRO Pivot
Leading Contract Research Organizations announce multi-million dollar investments in digital twin and OOC labs.
FDA Guidance on NAMs
The FDA issues initial framework for the submission of data derived from microphysiological systems.
FDA Modernization Act 2.0
President Biden signs legislation ending the mandate for animal testing for new drug applications.
U.S. abortions nearly doubled between 2021 and 2025, with medication abortion now 63% of the total. Telehealth delivery has enabled this surge, though misoprostol-only use raises clinical concerns.
Source: wyomingpublicmedia.org · news.wjct.org
A nationwide recall has been issued for a wellness supplement following the discovery of sildenafil, the active ingredient in the prescription drug Viagra. The presence of this undeclared pharmaceutical poses severe health risks, particularly through potentially fatal interactions with common heart medications.
Source: magic1079.iheart.com · love1011.iheart.com
A renewed public debate over Direct-to-Consumer Advertising (DTCA) is challenging the pharmaceutical industry's marketing status quo in the United States. As healthcare costs escalate, regulators and lawmakers are weighing the educational benefits of patient outreach against the risks of over-prescription and inflated drug prices.
The long-standing paradigm of animal experimentation is facing an unprecedented decline as regulatory frameworks and advanced biotechnologies converge. Following the landmark FDA Modernization Act 2.0, the industry is pivoting toward 'New Approach Methodologies' that promise higher human predictive value and lower development costs.
Food and Drug Administration (FDA) is linked from 4 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
